Novel Antibody-Drug Conjugate Shows Promise in Treating Relapsed Small Cell Lung Cancer

Recent findings from a pioneering Phase I clinical trial have unveiled encouraging results for SHR-4849 (IDE849), an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) in patients suffering from relapsed small cell lung cancer (SCLC). Presented at the 2025 World Conference on Lung Cancer by the International Association for the Study of Lung Cancer, these developments could mark a significant advancement in treatment options for this challenging disease.

According to the International Agency for Research on Cancer, lung cancer diagnoses reached 2.48 million in 2022, with small cell lung cancer accounting for 11.5% of cases in men and 9.7% in women. This form of cancer is notorious for its limited treatment avenues and poor prognosis.

SHR-4849 comprises a humanized IgG1 monoclonal antibody that specifically targets DLL3, linked to a DNA topoisomerase I inhibitor through a cleavable connector. Given DLL3's pronounced expression in SCLC, this drug is being evaluated as a targeted therapeutic option for patients with few alternatives.

In the trial led by researchers at the Affiliated Cancer Hospital of Shandong First Medical University, 54 patients were treated across five different dosage levels, ranging from 0.8 to 4.2 mg/kg. Among 42 evaluable patients, the objective response rate (ORR) reached 59.5%, while the disease control rate (DCR) was an impressive 90.5%. Notably, patients monitored for at least 12 weeks reported a higher ORR of 69.2%, with an even more promising 77.8% observed at the 2.4 mg/kg expansion dose.

The research team noted that the most frequently reported treatment-related side effects included decreased white blood cell counts, anemia, neutropenia, and nausea. Importantly, there were no treatment-related adverse events leading to discontinuation of the study drug or fatalities.

This study employed a dose-escalation and expansion methodology, achieving preliminary efficacy across several dose levels while maintaining a favorable safety profile. No dose-limiting toxicities were recorded at doses below 4.2 mg/kg, and plasma levels of the free toxin remained low across all administered doses.

As the trial progresses, dose expansion is ongoing to identify the recommended Phase II dose (RP2D). Continued clinical development will further explore the therapeutic potential of SHR-4849 for SCLC patients expressing DLL3.

These early results present a promising outlook for the treatment of DLL3-positive relapsed SCLC, suggesting that SHR-4849 could become a crucial option for patients facing limited therapeutic choices.